167 related articles for article (PubMed ID: 31151497)
1. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
[TBL] [Abstract][Full Text] [Related]
2. The safety and tolerability of the second-line injectable antituberculosis drugs in children.
Garcia-Prats AJ; Schaaf HS; Hesseling AC
Expert Opin Drug Saf; 2016 Nov; 15(11):1491-1500. PubMed ID: 27548570
[TBL] [Abstract][Full Text] [Related]
3. Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.
Arnold A; Cooke GS; Kon OM; Dedicoat M; Lipman M; Loyse A; Chis Ster I; Harrison TS
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696239
[TBL] [Abstract][Full Text] [Related]
4. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.
Sagwa EL; Souverein PC; Ribeiro I; Leufkens HG; Mantel-Teeuwisse AK
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):1-8. PubMed ID: 27868278
[TBL] [Abstract][Full Text] [Related]
5. Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
Wrohan I; Redwood L; Ho J; Velen K; Fox GJ
Int J Tuberc Lung Dis; 2021 Jan; 25(1):23-30. PubMed ID: 33384041
[No Abstract] [Full Text] [Related]
6. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
Shibeshi W; Sheth AN; Admasu A; Berha AB; Negash Z; Yimer G
BMC Pharmacol Toxicol; 2019 May; 20(1):31. PubMed ID: 31122273
[TBL] [Abstract][Full Text] [Related]
7. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.
Sturdy A; Goodman A; José RJ; Loyse A; O'Donoghue M; Kon OM; Dedicoat MJ; Harrison TS; John L; Lipman M; Cooke GS
J Antimicrob Chemother; 2011 Aug; 66(8):1815-20. PubMed ID: 21642291
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa.
Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
Am J Audiol; 2020 Jun; 29(2):199-205. PubMed ID: 32320639
[TBL] [Abstract][Full Text] [Related]
9. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
Sogebi OA; Adefuye BO; Adebola SO; Oladeji SM; Adedeji TO
Auris Nasus Larynx; 2017 Aug; 44(4):404-410. PubMed ID: 27832910
[TBL] [Abstract][Full Text] [Related]
10. Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.
Hong H; Dooley KE; Starbird LE; Francis HW; Farley JE
Arch Toxicol; 2019 May; 93(5):1385-1399. PubMed ID: 30963202
[TBL] [Abstract][Full Text] [Related]
11. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
Ramma L; Nhokwara PT; Rogers C
S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
[TBL] [Abstract][Full Text] [Related]
12. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis.
Dharmadhikari AS; Kabadi M; Gerety B; Hickey AJ; Fourie PB; Nardell E
Antimicrob Agents Chemother; 2013 Jun; 57(6):2613-9. PubMed ID: 23529740
[TBL] [Abstract][Full Text] [Related]
13. Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy.
Perumal R; Abdelghani N; Naidu N; Yende-Zuma N; Dawood H; Naidoo K; Singh N; Padayatchi N
J Acquir Immune Defic Syndr; 2018 Aug; 78(5):536-542. PubMed ID: 29683992
[TBL] [Abstract][Full Text] [Related]
14. High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
Souleymane MB; Piubello A; Lawan IM; Hassane-Harouna S; Assao-Neino MM; Soumana A; Hamidou-Harouna Z; Gagara-Issoufou A; Ortuño-Gutiérrez N; Roggi A; Schwoebel V; Mamadou S; Lynen L; De Jong B; Van Deun A; Decroo T
Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32703777
[TBL] [Abstract][Full Text] [Related]
15. [Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis].
Poka-Mayap V; Balkissou Adamou D; Pefura-Yone EW; Kuaban C
Rev Mal Respir; 2020 May; 37(5):369-375. PubMed ID: 32278508
[TBL] [Abstract][Full Text] [Related]
16. Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis.
Vasconcelos KA; Frota SMMC; Ruffino-Netto A; Kritski AL
J Bras Pneumol; 2018 Apr; 44(2):85-92. PubMed ID: 29791559
[TBL] [Abstract][Full Text] [Related]
17. Hearing loss in patients on treatment for drug-resistant tuberculosis.
Seddon JA; Godfrey-Faussett P; Jacobs K; Ebrahim A; Hesseling AC; Schaaf HS
Eur Respir J; 2012 Nov; 40(5):1277-86. PubMed ID: 22700838
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.
Hong H; Budhathoki C; Farley JE
Int J Tuberc Lung Dis; 2018 Jun; 22(6):667-674. PubMed ID: 29862952
[TBL] [Abstract][Full Text] [Related]
19. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.
Sagwa EL; Ruswa N; Mavhunga F; Rennie T; Leufkens HG; Mantel-Teeuwisse AK
BMC Pharmacol Toxicol; 2015 Dec; 16():36. PubMed ID: 26654443
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis.
Ghafari N; Court R; Chirehwa MT; Wiesner L; Petersen L; Maartens G; Gumbo T; McIlleron H; Ramma L
Int J Audiol; 2020 Mar; 59(3):219-223. PubMed ID: 31739701
[No Abstract] [Full Text] [Related]
[Next] [New Search]
